Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 March 2017Next earnings report:
04 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 21:58:44 GMTDividend
Analysts recommendations
Institutional Ownership
BYSI Latest News
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global biopharmaceutical company focused on developing new cancer treatments, announced that it held a virtual Research and Development (R&D) Day to discuss its main product Plinabulin, a dendritic cell (DC) maturation agent, in combination with other drugs to address unmet medical needs in cancer patients who have not responded to PD-1/PD-L1 inhibitors. The event also included updates on SEED Therapeutics, which uses a target protein degradation (TPD) platform for innovative molecular glue drug discovery, on May 15, 2024.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that management will present and participate in the R.W. Baird's 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.
What type of business is BeyondSpring?
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
What sector is BeyondSpring in?
BeyondSpring is in the Healthcare sector
What industry is BeyondSpring in?
BeyondSpring is in the Biotechnology industry
What country is BeyondSpring from?
BeyondSpring is headquartered in United States
When did BeyondSpring go public?
BeyondSpring initial public offering (IPO) was on 09 March 2017
What is BeyondSpring website?
https://www.beyondspringpharma.com
Is BeyondSpring in the S&P 500?
No, BeyondSpring is not included in the S&P 500 index
Is BeyondSpring in the NASDAQ 100?
No, BeyondSpring is not included in the NASDAQ 100 index
Is BeyondSpring in the Dow Jones?
No, BeyondSpring is not included in the Dow Jones index
When does BeyondSpring report earnings?
The next expected earnings date for BeyondSpring is 04 July 2024